光生物调节对头颈癌放疗患者口腔黏膜炎严重程度及分子变化的影响:成本-效果随机临床试验研究方案
本方案为随机双盲临床试验,拟纳入50例接受放疗或放化疗的头颈癌患者,随机分为光生物调节干预组与预防性口腔护理对照组。研究在第1、7、14、21、30次放疗时评估口腔黏膜炎、唾液炎症/氧化应激指标及生活质量,并从巴西公共卫生系统视角估算增量成本-效果比。
要点
- 光生物调节是防治重度口腔黏膜炎的成熟疗法,但以生活质量为主要效果指标的成本-效果证据尚缺。
- 本试验将比较光生物调节与预防性口腔护理,并检测唾液炎症介质与氧化应激水平。
- 结果为巴西公共卫生系统是否纳入该技术提供依据。
核心结论
- 研究旨在评估光生物调节预防和控制重度口腔黏膜炎的成本-效果及其对唾液炎症介质的影响。
- 作者指出光生物调节虽可降低口腔黏膜炎治疗成本,但其成本-效果(尤其以生活质量为效果指标)证据不足。
- 该疗法目前尚未获巴西公共卫生系统支持,本研究可为公共政策制定者与口腔护理专业人员提供信息。
研究设计与样本
- 随机、双盲临床试验,纳入50例接受放疗或放化疗的头颈癌患者。
- 参与者随机分为干预组(光生物调节)和对照组(预防性口腔护理方案)。
- 在第1、7、14、21和30次放疗时进行口腔黏膜炎临床评估、唾液采集和生活质量评估。
- 生活质量采用口腔健康影响程度量表-14(Oral Health Impact Profile-14)和患者报告口腔黏膜炎症状问卷评估。
- 测定所有参与者唾液样本中的氧化应激和炎症细胞因子水平,并按放疗时间区间识别、测量和评价成本,估算增量成本-效果比;研究采用巴西公共卫生系统视角。
关键数值与推荐
- 主要效果指标为生活质量,同时评估口腔黏膜炎严重程度与唾液炎症介质。
- 成本-效果以增量成本-效果比(ICER)估算,评价视角为巴西公共卫生系统。
临床怎么用
- 结果可用于判断光生物调节预防重度口腔黏膜炎是否兼具临床与成本-效果优势。
- 可为公共卫生系统是否纳入光生物调节技术及口腔护理人员开展该治疗提供依据。
局限性
- 本文为研究方案,尚未报告实际结果数据。
- 样本量为50例,研究在巴西公共卫生系统视角下开展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral mucositis (OM) is the most frequent and debilitating acute side effect associated with head and neck cancer (HNC) treatment. When present, severe OM negatively impacts the quality of life of patients undergoing HNC treatment. Photobiomodulation is a well-consolidated and effective therapy for the treatment and prevention of severe OM, and is associated with a cost reduction of the cancer treatment. Although an increase in the quality of life and a reduction in the severity of OM are well described, there is no study on cost-effectiveness for this approach considering the quality of life as a primary outcome. In addition, little is known about the photobiomodulation effects on salivary inflammatory mediators. Thus, this study aimed to assess the cost-effectiveness of the photobiomodulation therapy for the prevention and control of severe OM and its influence on the salivary inflammatory mediators. METHODS/DESIGN: This randomized, double-blind clinical trial will include 50 HNC patients undergoing radiotherapy or chemoradiotherapy. The participants will be randomized into two groups: intervention group (photobiomodulation) and control group (preventive oral care protocol). OM (clinical assessment), saliva (assessment of collected samples) and quality of life (Oral Health Impact Profile-14 and Patient-Reported Oral Mucositis Symptoms questionnaires) will be assessed at the 1st, 7th, 14th, 21st and 30th radiotherapy sessions. Oxidative stress and inflammatory cytokine levels will be measured in the saliva samples of all participants. The costs are identified, measured and evaluated considering the radiotherapy time interval. The incremental cost-effectiveness ratio will be estimated. The study will be conducted according to the Brazilian public health system perspective. DISCUSSION: Photobiomodulation is an effective therapy that reduces the cost associated with OM treatment. However, little is known about its cost-effectiveness, mainly when quality of life is the effectiveness measure. Additionally, this therapy is not supported by the Brazilian public health system. Therefore, this study widens the knowledge about the safety of and strengthens evidence for the use of photobiomodulation therapy, providing information for public policy-makers and also for dental care professionals. This study is strongly encouraged due to its clinical relevance and the possibility of incorporating new technology into public health systems. TRIAL REGISTRATION: Brazilian Registry of Clinical Trials-ReBEC, RBR-5h4y4n . Registered on 13 June 2017.
引用
- Martins AFL, Nogueira TE, Morais MO, et al. Effect of photobiomodulation on the severity of oral mucositis and molecular changes in head and neck cancer patients undergoing radiotherapy: a study protocol for a cost-effectiveness randomized clinical trial. Trials. 2019. PMID: 30709370. doi:10.1186/s13063-019-3196-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。